Abstract
Biobanks serve as the cornerstone of translational research. Evolving from traditional biobanks, living biobanks—particularly organoid living biobanks—have emerged as a critical and powerful platform, characterized by their three-dimensional biomimetic architecture, long-term self-renewal capacity, and retention of key genetic and pathological phenotypes of the parental tissue. At the pivotal juncture of a paradigm shift in biomedical research, organoids, as an important component of Novel Alternative Methods, hold broad prospects for both biomedical research and clinical applications. High-quality organoids can precisely recapitulate the structure and function of native organs, ensuring the accuracy and reproducibility of research outcomes. This establishes a robust foundation for investigating disease mechanisms, drug discovery, and precision medicine. Implementing rigorous quality control is therefore pivotal for guaranteeing research reliability and clinical applicability. The present article comprehensively examines the current landscape of tumor organoid quality control, covering critical quality control checkpoints across key technical stages of the construction process, advancements in standardization, and future development trends. By synthesizing these aspects, this work aims to empower researchers and practitioners to overcome challenges in quality control, enhance organoid fidelity, and accelerate the translation of organoid technology from fundamental research to clinical implementation.
Get full access to this article
View all access options for this article.
